Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,190 | 28 | 73.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,380 | 2 | 24.6% |
| Travel and Lodging | $801.23 | 5 | 1.0% |
| Food and Beverage | $642.42 | 14 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22,374 | 20 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $21,129 | 13 | $0 (2024) |
| Janssen Research & Development, LLC | $18,063 | 8 | $0 (2024) |
| Eli Lilly and Company | $17,500 | 1 | $0 (2020) |
| CSL Behring | $3,695 | 1 | $0 (2023) |
| Almirall LLC | $105.81 | 1 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $70.86 | 2 | $0 (2018) |
| Mallinckrodt LLC | $38.96 | 1 | $0 (2017) |
| Incyte Corporation | $23.13 | 1 | $0 (2022) |
| Janssen Biotech, Inc. | $14.34 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,536 | 13 | Novartis Pharmaceuticals Corporation ($7,673) |
| 2023 | $12,020 | 8 | CSL Behring ($3,695) |
| 2022 | $2,815 | 5 | Merck Sharp & Dohme LLC ($2,792) |
| 2021 | $11,220 | 4 | Novartis Pharmaceuticals Corporation ($10,620) |
| 2020 | $26,510 | 7 | Eli Lilly and Company ($17,500) |
| 2019 | $3,279 | 4 | Merck Sharp & Dohme Corporation ($3,173) |
| 2018 | $70.86 | 2 | Regeneron Healthcare Solutions, Inc. ($70.86) |
| 2017 | $6,564 | 6 | Merck Sharp & Dohme Corporation ($6,525) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $5,362.50 | General |
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| 11/06/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.84 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $200.64 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $158.85 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $65.50 | General |
| 06/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $40.31 | General |
| 06/14/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $378.36 | General |
| 05/17/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $4.93 | General |
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 11/20/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| 11/02/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Immunology | ||||||
| 10/13/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $35.44 | General |
| Category: Dermatology | ||||||
| 09/01/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 07/25/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 06/06/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 05/18/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 02/13/2023 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $3,695.00 | General |
| 11/30/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/15/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 06/22/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 03/27/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.13 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 247 | 476 | $58,816 | $16,083 |
| 2022 | 7 | 228 | 403 | $42,252 | $14,839 |
| 2021 | 11 | 287 | 490 | $62,794 | $20,869 |
| 2020 | 9 | 227 | 430 | $54,925 | $14,935 |
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17003 | Destruction of 2-14 skin growths | Facility | 2021 | 27 | 132 | $4,092 | $207.44 | 5.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 52 | 86 | $12,040 | $5,496 | 45.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 45 | 58 | $5,634 | $2,310 | 41.0% |
| 17000 | Destruction of skin growth | Facility | 2020 | 29 | 46 | $9,430 | $1,745 | 18.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $4,156 | $1,542 | 37.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 23 | $3,073 | $1,426 | 46.4% |
| 11104 | Punch biopsy of single skin lesion | Facility | 2020 | 21 | 22 | $10,659 | $926.59 | 8.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 11 | 11 | $2,553 | $708.16 | 27.7% |
| 11102 | Tangential biopsy of single skin lesion | Facility | 2020 | 19 | 21 | $2,730 | $519.86 | 19.0% |
| 17003 | Destruction of 2-14 skin growths | Facility | 2020 | 25 | 150 | $4,650 | $261.80 | 5.6% |
About Dr. Misha Rosenbach, MD
Dr. Misha Rosenbach, MD is a Internal Medicine healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659421790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Misha Rosenbach, MD has received a total of $83,014 in payments from pharmaceutical and medical device companies, with $20,536 received in 2024. These payments were reported across 49 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($61,190).
As a Medicare-enrolled provider, Rosenbach has provided services to 989 Medicare beneficiaries, totaling 1,799 services with total Medicare billing of $66,726. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Philadelphia, PA
- Active Since 01/11/2007
- Last Updated 11/28/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1659421790
Products in Payments
- COSENTYX (Biological) $7,380
- MK-1654 (Drug) $500.00
- DUPIXENT DUPILUMAB INJECTION (Biological) $70.86
- ACTHAR (Biological) $38.96
- COSENTYX (Drug) $35.44
- OPZELURA (Drug) $23.13
- TREMFYA (Drug) $14.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Philadelphia
Pitamber Devgon, Md, MD
Internal Medicine — Payments: $7.5M
Dr. David Horn, M.d, M.D
Internal Medicine — Payments: $1.7M
Daniel Rader, Md, MD
Internal Medicine — Payments: $1.6M
Corey Langer, Md, MD
Internal Medicine — Payments: $742,647
Dr. Intekhab Ahmed, M.d, M.D
Internal Medicine — Payments: $621,997
David Goldmann, Md, MD
Internal Medicine — Payments: $587,696